Advertisement

Predictive Biomarkers and Targeted Therapies in Genitourinary Cancers

  • Li Yan Khor
  • Puay Hoon Tan
Chapter

Abstract

Targeted therapies have unique roles in the management of genitourinary cancers. To date, many biomarkers which are directly involved in the pathways of action of these agents have not proven effective. Most recently, an immunotherapy agent was approved by the FDA for the treatment of metastatic urothelial cancer, with PD-L1 expression as its predictive marker of response. Newer markers which show promise are those identified by molecular techniques such as genotyping or next-generation sequencing of either tumor tissue or circulating tumor cells/DNA. This sophisticated precision medicine strategy shows promise in identifying novel predictors of patient response to targeted therapies.

Keywords

Targeted therapy Immunotherapy Next-generation sequencing Immune checkpoint inhibitors PD1/PD-L1 

References

  1. 1.
    Konda B, Kirschner LS. Novel targeted therapies in adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2016;23(3):233–41.  https://doi.org/10.1097/MED.0000000000000247.CrossRefGoogle Scholar
  2. 2.
    Millis SZ, Ejadi S, Demeure M. Molecular profiling of refractory adrenocortical cancers and predictive biomarkers to therapy. J Biomark Cancer. 2015;7:69–76.  https://doi.org/10.4137/BIC.S34292. eCollection 2015.CrossRefGoogle Scholar
  3. 3.
    Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010;65(4):765–73.CrossRefGoogle Scholar
  4. 4.
    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRefGoogle Scholar
  5. 5.
    Zhang T, Zhu J, George DJ, Nixon AB. Metastatic clear cell renal cell carcinoma: circulating biomarkers to guide antiangiogenic and immune therapies. Urol Oncol. 2016;34(11):510–8.  https://doi.org/10.1016/j.urolonc.2016.06.020.CrossRefGoogle Scholar
  6. 6.
    Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, et al. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Sci Rep. 2017;7:41371.  https://doi.org/10.1038/srep41371.CrossRefGoogle Scholar
  7. 7.
    García-Donas J, Beuselinck B, Inglada-Pérez L, Graña O, Schöffski P, Wozniak A, et al. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight. 2016;1(10):e86051.CrossRefGoogle Scholar
  8. 8.
    Escudier B, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–68.CrossRefGoogle Scholar
  9. 9.
    Rini BI, McDermott DF, Hammers H, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4:81.CrossRefGoogle Scholar
  10. 10.
    Jones RT, Felsenstein KM, Theodorescu D.Pharmacogenomics: biomarker-directed therapy for bladder cancer. Urol Clin N Am. 2016;43(1):77–86.  https://doi.org/10.1016/j.ucl.2015.08.007.CrossRefGoogle Scholar
  11. 11.
    Bellmunt J, et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii40–8.CrossRefGoogle Scholar
  12. 12.
    Contreras-Sanz A, Roberts ME, Seiler R, Black PC. Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. Int J Urol. 2017;24(1):7–15.  https://doi.org/10.1111/iju.13193.CrossRefGoogle Scholar
  13. 13.
    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194(6):1537–47.  https://doi.org/10.1016/j.juro.2015.06.106.CrossRefGoogle Scholar
  14. 14.
    Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics. Eur Urol. 2017;71(2):237–46.  https://doi.org/10.1016/j.eururo.2016.08.024.CrossRefGoogle Scholar
  15. 15.
    Miyamoto DT, Lee RJ. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: tools for real-time precision medicine? Urol Oncol. 2016;34(11):490–501.  https://doi.org/10.1016/j.urolonc.2016.09.001.CrossRefGoogle Scholar
  16. 16.
    McNeel DG, Bander NH, Beer TM, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016;4:92.CrossRefGoogle Scholar
  17. 17.
    Fankhauser CD, Honecker F, Beyer J, Bode PK. Emerging therapeutic targets for male germ cell tumors. Curr Oncol Rep. 2015;17(12):54.  https://doi.org/10.1007/s11912-015-0479-4.CrossRefGoogle Scholar
  18. 18.
    Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C. Investigational targeted therapies for the treatment of testicular germ cell tumors. Expert Opin Investig Drugs. 2016;25(9):1033–43.  https://doi.org/10.1080/13543784.2016.1195808.CrossRefGoogle Scholar
  19. 19.
    McDaniel AS, Hovelson DH, Cani AK, et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Cancer Res. 2015;75(24):5219–27.  https://doi.org/10.1158/0008-5472.CAN-15-1004.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Anatomical PathologySingapore General HospitalSingaporeSingapore
  2. 2.Division of PathologySingapore General HospitalSingaporeSingapore

Personalised recommendations